Subunit-dependent modulation of 5-HT3 receptor by anticancer drugs

2014 Fiscal Year Final Research Report

• Project/Area Number: 25861560
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Otorhinolaryngology
• Research Institution: Osaka University
• Principal Investigator: YUKIKO Nakamura 大阪大学, 医学(系)研究科(研究院), 助教 (90548083)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: セロトニン３受容体 / 抗癌剤

Outline of Final Research Achievements

It has been shown that anti-cancer drug induces secretion of serotonin (5-HT) from small intestine which activates serotonin type 3 (5-HT3) receptor to cause nausea and vomiting. In general, antagonist for 5-HT3 receptor is used as anti-emetics during chemotherapy. Previously, we reported that anti-cancer drug irinotecan itself inhibits 5-HT-gated current through the homomeric 5-HT3 receptor. Therefore we focused frequently-used anticancer drug to examine its effect to 5-HT3 receptor. More than 25% anticancer drugs modified 5-HT3 receptor response. Our finding suggested that these anticancer drugs could affect to anti-emetic activities through 5-HT3 receptor.

Free Research Field

薬理学、組織学、分子生物学